Results 1 to 10 of about 76,712 (310)

Persistence of biological agents over an eight-year period in rheumatoid arthritis and spondyloarthritis patients [PDF]

Farmacia Hospitalaria, 2019
Objective: To calculate the persistence, over a period of eight years, the retention rate of first and second-line of treatment with biological agents in patients with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis and to compare ...
María Ángeles González-Fernández , Elena Villamañán , Inmaculada Jiménez-Nácher , Francisco Moreno , Alicia Herrero , Alejandro Balsa   +5 more
doaj   +5 more sources

The Interleukine-17 Cytokine Family: Role in Development and Progression of Spondyloarthritis, Current and Potential Therapeutic Inhibitors

Biomedicines, 2023
Spondyloarthritis (SpA) encompasses a group of chronic inflammatory rheumatic diseases with a predilection for the spinal and sacroiliac joints, which include axial spondyloarthritis, psoriatic arthritis, reactive arthritis, arthritis associated with ...
Anna Davydova, Yuliya Kurochkina, Veronika Goncharova, Mariya Vorobyeva, Maksim Korolev   +4 more
doaj   +2 more sources

MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group [PDF]

Annals of the Rheumatic Diseases, 2019
Objectives The Assessment of SpondyloArthritis international Society (ASAS) MRI working group (WG) was convened to generate a consensus update on standardised definitions for MRI lesions in the sacroiliac joint (SIJ) of patients with spondyloarthritis ...
Walter P. Maksymowych, R. Lambert, Mikkel Østergaard, Susanne Juhl Pedersen, Pedro Machado, Ulrich Weber, Alexander N. Bennett, Juergen Braun, Rubén Burgos‐Vargas, Manouk de Hooge, Atul Deodhar, Iris Eshed, Anne Grethe Jurik, Kay‐Geert Hermann, Robert Landewé, Helena Marzo‐Ortega, Victoria Navarro‐Compán, Denis Poddubnyy, M. Reijnierse, Martín Rudwaleit, Joachim Sieper, Filip Van den Bosch, Désirée van der Heijde, Irene E. van der Horst‐Bruinsma, Stephanie Wichuk, Xenofon Baraliakos   +25 more
openalex   +2 more sources

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

Annals of the Rheumatic Diseases, 2022
Objectives To update the Assessment of SpondyloArthritis international Society (ASAS)-EULAR recommendations for the management of axial spondyloarthritis (axSpA).
S. Ramiro, E. Nikiphorou, A. Sepriano, A. Ortolan, C. Webers, X. Baraliakos, Robert B. M. Landewé, F. E. Van den Bosch, B. Boteva, A. Bremander, P. Carron, A. Ciurea, F. V. van Gaalen, P. Géher, L. Gensler, J. Hermann, M. de Hooge, M. Hušáková, U. Kiltz, C. López-Medina, P. Machado, H. Marzo-Ortega, A. Moltó, V. Navarro-Compán, M. Nissen, F. Pimentel-Santos, D. Poddubnyy, F. Proft, M. Rudwaleit, Mark Telkman, S. Zhao, N. Ziadé, D. van der Heijde   +32 more
semanticscholar   +1 more source

Extra-musculoskeletal manifestations driving the therapeutic decision-making in patients with Spondyloarthritis: a 12-month follow-up prospective cohort study

Advances in Rheumatology, 2023
Background The extra-musculoskeletal manifestations (EMMs) such as recurrent acute anterior uveitis (rAAU), psoriasis (Ps), and inflammatory bowel disease (IBD), are related to the Spondyloarthritis (SpA), as well as they are associated with disease ...
Danielle dos Reis Annunciato, Thauana Luiza Oliveira, Vanessa Oliveira Magalhães, Marcelo de Medeiros Pinheiro   +3 more
doaj   +1 more source

Association of Genetic Marker HLA-B27 with Spondyloarthritis In A Tertiary Care Centre In South India

Journal of Pure and Applied Microbiology, 2022
Human leukocyte antigens (HLA) are gene products found in the major histocompatibility complex, aiding in differentiation of “self” from “non-self” antigens, and is crucial for the communication between immune cells of the human body.
T. Jayaprakash, Om Lokesh Muthamilan, K.V. Leela, C. Panchapakesa Rajendran, Arul Raja Murugan, Sujith Ravi   +5 more
doaj   +1 more source

Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials

Annals of the Rheumatic Diseases, 2023
Objectives Axial spondyloarthritis (axSpA) is a complex disease with diverse manifestations, for which new treatment options are warranted. BE MOBILE 1 (non-radiographic (nr)-axSpA) and BE MOBILE 2 (radiographic axSpA (r-axSpA)) are double-blind, phase 3
D. van der Heijde, A. Deodhar, X. Baraliakos, Matthew A Brown, H. Dobashi, M. Dougados, D. Elewaut, Alicia M. Ellis, C. Fleurinck, K. Gaffney, L. Gensler, N. Haroon, M. Magrey, W. Maksymowych, Alexander Marten, U. Massow, M. Oortgiesen, D. Poddubnyy, M. Rudwaleit, J. Shepherd-Smith, T. Tomita, F. E. Van den Bosch, T. Vaux, Huji Xu   +23 more
semanticscholar   +1 more source

Differentiating nonradiographic axial spondyloarthritis from its mimics: a narrative review

BMC Musculoskeletal Disorders, 2022
Background Optimal treatment of nonradiographic axial spondyloarthritis depends on accurate and timely diagnosis of the underlying disease; however, patients present with common symptoms that, in the absence of radiographic changes, may confound ...
Philip Mease, Atul Deodhar
doaj   +1 more source

Axial and peripheral spondyloarthritis triggered by sars-cov-2 infection: a report of two cases

Reumatismo, 2021
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can show musculoskeletal symptoms such as peripheral arthritis. In rare cases, peripheral arthritis can develop after the resolution of SARS-CoV-2.
G. El Hasbani, A. Jawad, I. Uthman
doaj   +1 more source

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). [PDF]

, 2020
OBJECTIVES: To investigate the efficacy and safety of ixekizumab for up to 52 weeks in two phase 3 studies of patients with active radiographic axial spondyloarthritis (r-axSpA) who were biological disease-modifying antirheumatic drug (bDMARD)-naive ...
Baraliakos, X., Bertram, C.C., Bosch, F. van den, Carlier, H., COAST-V Study Grp, COAST-W Study Grp, Deodhar, A., Dougados, M., Ermann, J., Gallo, G., Gensler, L.S., Heijde, D. van der, Landewe, R., Li, X.Q., Maksymowych, W.P., Sieper, J., Tomita, T., Walsh, J.A., Wei, J.C.C., Zhao, F.Y.   +19 more
core   +3 more sources